Cancer stem cell immunoediting by IFNγ

被引：0
作者：
Claudia Galassi
Lorenzo Galluzzi
机构：
[1] Weill Cornell Medical College,Department of Radiation Oncology
[2] Sandra and Edward Meyer Cancer Center,undefined
[3] Caryl and Israel Englander Institute for Precision Medicine,undefined
来源：
Cell Death & Disease | / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The secretion of interferon gamma (IFNG, best known as IFNγ) by immune effector cells generally mediates potent anticancer effects. Recent data from Beziaud et al. demonstrate that—at least in some circumstances—IFNγ can edit the breast cancer microenvironment to promote stemness, disease progression and resistance to (immuno)therapy.
引用
收藏
相关论文
共 46 条
[1]  
Galluzzi L(2018)The hallmarks of successful anticancer immunotherapy Sci Transl Med 10 eaat7807-72
[2]  
Chan TA(2022)Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22 158-41
[3]  
Kroemer G(2022)Overcoming the limitations of cytokines to improve cancer therapy Int Rev Cell Mol Biol 369 107-14
[4]  
Wolchok JD(2015)Type I interferons in anticancer immunity Nat Rev Immunol 15 405-92
[5]  
Lopez-Soto A(2022)Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B Nat Immunol 23 1379-36
[6]  
Gocher AM(2022)Type I interferon induces cancer stem cells-mediated chemotherapy resistance Oncoimmunology 11 2127274-31.e6
[7]  
Workman CJ(2021)Cancer stem cell-immune cell crosstalk in tumour progression Nat Rev Cancer 21 526-19
[8]  
Vignali DAA(2023)IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy Cell Stem Cell 30 818-62
[9]  
Di Trani CA(2017)DNA damage in stem cells Mol Cell 66 306-undefined
[10]  
Cirella A(2018)Hyperprogressive disease: recognizing a novel pattern to improve patient management Nat Rev Clin Oncol 15 748-undefined
12345